A Phase 3 trial for Eli Lilly’s monoclonal antibody COVID-19 treatment has been paused following a potential safety concern.
The trial, called ACTIV-3, is studying Eli Lilly’s monoclonal antibody treatment, plus remdesivir, in hospitalized patients.
Monoclonal antibodies are synthetic versions of the natural antibodies made in response to infection.
Eli Lilly said in a statement: “Out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment. … Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study.”
